Seelos Therapeutics Inc. Stock News

Brokerages expect Seelos Therapeutics, Inc. (NASDAQ:SEEL) to report earnings per share (EPS) of ($0.12) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Seelos Therapeutics earnings. The lowest EPS estimate is ($0.12) and the highest is ($0.11). Seelos Therapeutics reported earnings of ($0.13) per share during the same quarter []

Seelos Therapeutics, Inc. (NASDAQ:SEEL) with the stream of 1.23% also noticed, India Regis Corporation (NYSE:RGS) encountered a rapid change of -2.46% in the last hour of Fridays trading session. Seelos The post Undertaking Stock: Seelos Therapeutics, Inc. (NASDAQ:SEEL), Regis Corporation (NYSE:RGS) appeared first on Stocks Equity .

The stock price of Seelos Therapeutics Inc (NASDAQ: SEEL) fell by 6.47% today. This is why it happened.

The trading price of Seelos Therapeutics Inc. (NASDAQ:SEEL) closed lower on Monday, December 13, closing at $1.70, -1.73% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S

Seelos Therapeutics, Inc. (SEEL) with the stream of -5.75% also noticed, India Allied Healthcare Products, Inc. (AHPI) encountered a rapid change of -11.82% in the last hour of Fridays trading The post Have an eye on: Seelos Therapeutics, Inc. (NASDAQ:SEEL), Allied Healthcare Products, Inc. (NASDAQ:AHPI) appeared first on Stocks Equity .

Wall Street brokerages expect Seelos Therapeutics, Inc. (NASDAQ:SEEL) to post ($0.12) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Seelos Therapeutics earnings, with estimates ranging from ($0.12) to ($0.11). Seelos Therapeutics reported earnings per share of ($0.13) in the same quarter last year, which suggests a positive []

IX BIOPHARMA LTD. ( SGX:42C ) iX Biopharma - Just A Warm Up iX Biopharma (SGX:42C) signs out-licensing agreement for its Wafermine drug worth more than S$300mil (excluding royalties) with Nasdaq-listed Seelos Therapeutics . Seelos provides the regulatory, clinical development and local USA market knowledge to register and commercialise Wafermine and other ketamine-related products. Seelos will fund future development, manufacturing and commercialisation of Wafermine and related drugs. iX Biopharma will receive an upfront payment, development milestone, sales milestone and royalties. Continue Reading »

Nuveen Asset Management LLC purchased a new stake in Seelos Therapeutics, Inc. (NASDAQ:SEEL) in the second quarter, Holdings Channel.com reports. The fund purchased 162,606 shares of the companys stock, valued at approximately $429,000. A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. First []

(RTTNews) - iX Biopharma said that it will license to Seelos Therapeutics Inc (SEEL) its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology. As per the license agreement, iX Biopharma will receive a US$9 million upfront

Seelos Therapeutics (NASDAQ:SEEL) and Kadmon (NASDAQ:KDMN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings & Valuation This table compares Seelos Therapeutics and Kadmons revenue, earnings per share and valuation. []

Seelos Therapeutics, Inc. (NASDAQ:SEEL) has earned a consensus rating of Buy from the six research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued [] The post Seelos Therapeutics, Inc. (NASDAQ:SEEL) Receives Consensus Recommendation of Buy from Brokerages appeared first on ETF Daily News .

Northern Trust Corp increased its stake in Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 520.8% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 760,056 shares of the companys stock after buying an additional 637,626 shares during the period. Northern Trust Corp owned 0.97% of Seelos Therapeutics []

Equities research analysts expect that Seelos Therapeutics, Inc. (NASDAQ:SEEL) will post earnings per share (EPS) of ($0.11) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Seelos Therapeutics earnings. Seelos Therapeutics reported earnings of ($0.13) per share in the same quarter last year, which would suggest a positive year over []